- Trials with a EudraCT protocol (43)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
43 result(s) found for: Limb perfusion.
Displaying page 1 of 3.
EudraCT Number: 2014-000377-40 | Sponsor Protocol Number: MST-188-07 | Start Date*: 2014-11-13 | |||||||||||
Sponsor Name:Mast Therapeutics, Inc. | |||||||||||||
Full Title: Evaluation of MST-188 in Acute Lower Limb Ischemia: A Phase 2 Randomized Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial Evaluating the Safety and Efficacy Of MST-188 in Subjects with... | |||||||||||||
Medical condition: Acute Lower Limb Ischemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004200-21 | Sponsor Protocol Number: SUGBG-KIR-2018-001 | Start Date*: 2018-10-05 | |||||||||||
Sponsor Name:Sahlgrenska University Hospital | |||||||||||||
Full Title: A phase Ib/II randomized double-blind placebo controlled trial evaluating the effect of nivolumab for patients with in-transit melanoma metastases treated with isolated limb perfusion | |||||||||||||
Medical condition: Malignant melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004281-18 | Sponsor Protocol Number: NC12547 | Start Date*: 2020-08-18 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Clonidine for Tourniquet-related Pain in Children (CLOTCH) -Study: A Pilot Study | |||||||||||||
Medical condition: Pain, which occurs in relation to the use of tourniquets during limb surgery. Tourniquets are positioned on the upper part of the limb in question, inflated and thereby stops perfusion of the limb.... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004684-40 | Sponsor Protocol Number: N-O_CLI_Study | Start Date*: 2018-04-19 | |||||||||||
Sponsor Name:Krakowski Szpital Specjalistyczny im. Jana Pawła II | |||||||||||||
Full Title: Regeneration of ischemic damages in cardiovascular system using Wharton’s jelly as an unlimited source of mesenchymal stem cells for regenerative medicine. Project of the National Centre for Resear... | |||||||||||||
Medical condition: Critical limb ischemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006277-24 | Sponsor Protocol Number: EFC6145 | Start Date*: 2008-04-10 | |||||||||||
Sponsor Name:sanofi-aventis recherche et développement | |||||||||||||
Full Title: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 4 ADMINISTRATIONS OF XRP0038/NV1FGF 4mg AT 2–WEEK INTERVALS ON AMPUTATION OR ANY DEATH IN CRITICAL LI... | |||||||||||||
Medical condition: Critical Limb Ischemia with skin lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) HU (Completed) GB (Completed) CZ (Completed) GR (Completed) ES (Completed) AT (Completed) FI (Completed) SE (Completed) FR (Completed) EE (Completed) IT (Completed) DK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002940-22 | Sponsor Protocol Number: STARDUST | Start Date*: 2021-01-13 | |||||||||||
Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli" | |||||||||||||
Full Title: EFFECTS OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE ON LOWER LIMB PERFUSION IN PEOPLE WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A RANDOMIZED CONTROLLED TRIAL | |||||||||||||
Medical condition: Peripheral Artery Disease and type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001970-29 | Sponsor Protocol Number: SP777 | Start Date*: 2005-10-14 | |||||||||||
Sponsor Name:Schwarz Pharma Deutschland GmbH | |||||||||||||
Full Title: Multinational, prospective, randomized, double-blind, placebo-controlled, parallel groups study to assess the efficacy and safety of Prostaglandin E1 in subjects with circulatory disturbance of a limb | |||||||||||||
Medical condition: Peripheral arterial occlusive disease (PAOD) Fontaine stage IV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005723-20 | Sponsor Protocol Number: RC31/20/0445 | Start Date*: 2022-02-10 |
Sponsor Name:CHU de Toulouse | ||
Full Title: Evaluation of Botulinum TOXin type A in the treatment of Buerger’s disease | ||
Medical condition: This study assesses the feasibility and safety of treatment with botulinum toxin injection in patients with Buerger's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004125-24 | Sponsor Protocol Number: NL6979 | Start Date*: 2020-07-02 |
Sponsor Name:UMCG | ||
Full Title: Reduced Anticoagulation Targets in Extracorporeal life support | ||
Medical condition: Heart or lungfailure treated with ECMO | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001083-43 | Sponsor Protocol Number: BAY 59-7939 / 11223 | Start Date*: 2004-11-23 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis ODIXa-DVT A prospective, randomized, multinational, multicenter, partially blinded, parallel-grou... | |||||||||||||
Medical condition: Acute deep vein thrombosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002171-16 | Sponsor Protocol Number: BAY 59-7939 / 11528 | Start Date*: 2005-01-10 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. | |||||||||||||
Medical condition: Acute syntomatic deep vein thrombosis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004953-27 | Sponsor Protocol Number: CV185-057 | Start Date*: 2008-07-29 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm an... | ||||||||||||||||||
Medical condition: Venous Thromboembolism (VTE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) PT (Completed) GB (Completed) AT (Completed) DK (Completed) CZ (Completed) IT (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003342-25 | Sponsor Protocol Number: P170604J | Start Date*: 2018-09-07 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Long-term treatment of cancer associated VTE Optimal dose of apixaban API-CAT STUDY for APIxaban Cancer Associated Thrombosis | |||||||||||||
Medical condition: Patients with breast, prostate, and colorectal active cancer, with objectively documented index event of symptomatic or incidental proximal DVT or symptomatic or incidental PE, after 6 months of an... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PL (Ongoing) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) GR (Completed) AT (Ongoing) NL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013498-17 | Sponsor Protocol Number: IC ClearLy | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Cardiologia - Azienda Ospedaliero Universitaria di Modena | |||||||||||||
Full Title: IntraCoronary Abciximab with the ClearWay Catheter To Improve Outcomes with Lysis (IC ClearLy) Trial | |||||||||||||
Medical condition: The study will enroll male or female ACS patients at least 18 years of age presenting with STEMI with angiographically visible thrombus (Thrombus Grade >2) who are planned to undergo emergency PCI ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005112-15 | Sponsor Protocol Number: TARTARE-2S-01 | Start Date*: 2016-09-29 | |||||||||||
Sponsor Name:Inselspital, Universitätspital Bern | |||||||||||||
Full Title: TARGETED TISSUE PERFUSION VERSUS MACROCIRCULATORY-GUIDED STANDARD CARE IN PATIENTS WITH SEPTIC SHOCK (TARTARE-2S) | |||||||||||||
Medical condition: Critically ill adult patients with septic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001235-20 | Sponsor Protocol Number: 14.0189 | Start Date*: 2015-06-05 |
Sponsor Name:St George's University of London | ||
Full Title: Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease | ||
Medical condition: PARTICIPANTS WITH EVIDENCE OF CEREBRAL SMALL VESSEL DISEASE | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-001697-58 | Sponsor Protocol Number: 2128/2021 | Start Date*: 2022-12-20 |
Sponsor Name:Medical University of Vienna | ||
Full Title: An investigation of clinical outcomes and inflammatory response to heparin free extracorporeal membrane oxygenation support during clinical lung transplantation – a prospective double-blind randomi... | ||
Medical condition: Intraoperative extra-corporeal membrane oxygenation during lung transplantation for end-stage lung disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003743-10 | Sponsor Protocol Number: 2016-779 | Start Date*: 2017-02-06 |
Sponsor Name:Herlev og Gentofte Hospital | ||
Full Title: Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at high cardiovascular risk: The SIMPle Randomized Clinical Trial | ||
Medical condition: Type 2 diabetes and cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016178-33 | Sponsor Protocol Number: 1245.25 | Start Date*: 2010-11-12 | |||||||||||
Sponsor Name:Boehringer Ingelheim B.V. | |||||||||||||
Full Title: A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in ... | |||||||||||||
Medical condition: The study will be performed in patients with type 2 diabetes mellitus and high cardiovascular risk who have insufficient glycaemic control despite diet and exercise and are either treatment naïve o... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) HU (Completed) PT (Completed) GB (Completed) AT (Completed) GR (Completed) PL (Completed) EE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007867-25 | Sponsor Protocol Number: CV185-056 | Start Date*: 2008-08-26 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism. Revised Protocol Number 02 incorporating Amendment(s) 04... | ||||||||||||||||||
Medical condition: Venous Thromboembolism (VTE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) AT (Completed) HU (Completed) ES (Completed) PT (Completed) DK (Completed) CZ (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
